CLINICAL TRIALS PROFILE FOR COSENTYX
✉ Email this page to a colleague
All Clinical Trials for COSENTYX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02144857 ↗ | Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis | Recruiting | University of Athens | Phase 4 | 2014-05-30 | Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in patients with psoriasis compared to normal controls ,coronary artery disease patients and untreated hypertension subjects. The investigators also examined the effect of treatment with biological vs no biological agents on vascular and LV function in psoriasis. |
| NCT02592018 ↗ | Immunologic Response to Secukinumab in Plaque Psoriasis | Completed | Novartis Pharmaceuticals | Phase 4 | 2016-10-01 | This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions. |
| NCT02592018 ↗ | Immunologic Response to Secukinumab in Plaque Psoriasis | Completed | University of California, San Francisco | Phase 4 | 2016-10-01 | This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions. |
| NCT02778711 ↗ | Anti-IL-17 a New Treatment for Contact Dermatititis | Unknown status | Tanja Todberg, MD | Phase 3 | 2016-01-01 | The purpose of this study is to assess the efficacy of anti-IL 17 treatment (secukinumab) in patients with known severe allergic contact dermatitis (ACD). |
| NCT02854163 ↗ | Effect of Secukinumab in the Treatment of Psoriatic Arthritis | Completed | Novartis | Phase 2 | 2016-10-15 | The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab, with respect to efficacy and adverse events. The results of this secondary exploratory analysis will inform the design of a larger, definitive study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for COSENTYX
Condition Name
Clinical Trial Locations for COSENTYX
Trials by Country
Clinical Trial Progress for COSENTYX
Clinical Trial Phase
Clinical Trial Sponsors for COSENTYX
Sponsor Name
